

Special Issue

Allergic Contact Dermatitis: Pathology, Comorbidities, and Treatment

Message from the Guest Editor

Allergic contact dermatitis (ACD) is a prevalent form of eczema that affects the general population, regardless of the age and or sex. The pathophysiology of ACD is very interesting given that each allergen can mediate a characteristic immune-mediated reaction. The use of immunomodulators during the week of the study may alter the results by blocking certain inflammatory pathways, such as inflammation mediated by Th2 lymphocytes. Comorbidities associated with ACD have not been specially studied. Although the treatment of ACD is avoidance of the detected allergen, topical and systemic treatments outside the technical specifications are sometimes required. We look forward to discussing these topics in this Special Issue.

- allergic contact dermatitis
- patch test
- pathophysiology
- comorbidities
- psychodermatosis
- treatment

Guest Editor

Dr. Francisco Navarro-Triviño

Contact Eczema and Immunoallergic Diseases, Dermatology Department, Hospital Universitario San Cecilio, Avda. del Conocimiento s/n, 18016 Granada, Spain

Deadline for manuscript submissions

closed (30 September 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/199097

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).